Tranexamic Acid for the Treatment of Advanced Ovarian Carcinoma

Abstract

In the present phase II trial, 26 heavily pretreated patients with advanced recurrent ovarian carcinoma were treated with tranexamic acid, 4-6 g per os daily for at least 3 months. Of these 26 patients, 3 had stage IIb, 21 stage III and 2 stage IV. Histologic examination revealed serous adenocarcinoma in 13, mucinous in 3, endometroid in 4, 1 anaplastic and 5 unspecified adenocancer. Twenty of the tumors were poorly differentiated and 5 highly-moderately differentiated. No objective response was noted but all the highly-moderately differentiated tumors showed a stable disease state with a median duration of 6 months (range 4-36 months). The patients with poorly differentiated tumors had a median survival of 4 months. Most of the patients had some form of gastro-intestinal side effect. This investigation has shown that treatment with tranexamic acid was not particularly helpful in poorly differentiated cases in which modern combined chemotherapy already had failed. The effect in highly-moderately differentiated cases needs further evaluation.

Response of Rat Prostate and Lung Tumors to Ionizing Radiation Combined with the Angiogenesis Inhibitor AMCA

“…Inhibition was apparently caused by increased fibrin deposition at the advancing border of tumors due to reduced fibrinolytic activity [23]. Several preclinical as well as clinical studies have reported promising effects of this drug on endothelial cell invasion, angiogenesis, tumor growth and metastasis [1,3,5,6,11,28,29,32,43,44]. Cyklokapron ® is a registered medicine, cheap and easy available and is in use for prevention of bleeding of intracranial aneurysm, treatment of patients with bleeding or risk of bleeding of primary and secondary hyperfibrinolysis or fibrinogenolysis, and hereditary angioedema.…”

Tumor growth and metastasis are not affected in thrombin‐activatable fibrinolysis inhibitor‐deficient mice

“…These lysine analogs inhibit angiogenesis, tumor cell metastasis and primary tumor growth. Moreover, beneficial effects of these compounds have been reported in cancer patients [32,33].…”

TAFI and Pancreatic Carboxypeptidase B Modulate In Vitro Capillary Tube Formation by Human Microvascular Endothelial Cells

“…15 Lysine analogs, such as -amino-caproic acid (-ACA) and tranexamic acid (Cyclokapron) efficiently prevent plasmin formation 16 and inhibit tumor cell metastasis and primary tumor growth. 17,18 Moreover, binding of plasminogen to the cell surface can be abrogated by treatment with pancreatic CPB as well as with TAFIa. 19 It is therefore possible that TAFI functions as a broad modulator of the plasminogen system in its various functions.…”